Compare General Motors Company (GM) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Motors Company vs IDEXX Laboratories, Inc. — how do they compare? General Motors Company trades at $76.8 (market cap $70.01B), while IDEXX Laboratories, Inc. trades at $572.7 (market cap $43.94B). The key difference: General Motors Company is the larger of the two by market cap, and General Motors Company pays a 0.93% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| GM | IDXX | |
|---|---|---|
Market Cap | $70.01B | $43.94B |
Sector | Consumer Cyclical | Health |
52-Week High | $86.38 | $766.68 |
52-Week Low | $48.89 | $514.61 |
Enterprise Value | $173.34B | $44.84B |
Dividend Yield | 0.93% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Motors (GM) trades at $76.87, up 0.2% daily, with a neutral technical signal. The company shows strong operational cash flow of $26.87B in 2025 and has beaten earnings estimates for three consecutive quarters. Valuation metrics appear attractive with P/S of 0.4 and P/B of 1.12, while analyst consensus remains bullish with a $102 price target representing 33% upside potential.
GM presents a value opportunity with depressed valuation multiples despite recent earnings beats and solid cash generation. Key risks include declining profit margins (1.38% net margin in 2025), competitive pressures in the EV transition, and elevated debt levels. The stock's appeal hinges on margin stabilization and successful execution of strategic initiatives amid industry headwinds.
IDXX stock trades at $540.68, down 4.15% in the last session, with technical indicators showing a bearish bias. Fundamentally, the company demonstrates strong profitability with a 24.63% net margin and consistent earnings beats in recent quarters. Revenue growth continues, reaching $4.3B in 2025. Analyst sentiment remains predominantly positive with a 59% buy rating, though technical signals conflict with this fundamental strength.
The outlook balances robust fundamentals against technical weakness. Investment opportunity lies in sustained high profitability and market leadership in veterinary diagnostics, but risks include elevated valuation multiples (P/E 40.99) and bearish technical momentum that may pressure the stock near-term despite positive analyst coverage.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Motors Company
General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company lost its U.S. market share leader crown in 2021 with share down 280 basis points to 14.6%, but we expect GM to reclaim the top spot in 2022 as 2021 suffered from the chip shortage. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.
Read more on GM →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
